• Azizi H, Hassani K, Taslimi Y, Shateri Najafabadi H, Papadopoulou B and Rafati S. Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology, in press 2009

  •  Bolhassani A., Ghasemi N., Servis C., Taghikhani M. and Rafati S. The Efficiency of a Novel Delivery System (PEI600-Tat) in Development of Potent DNA Vaccine Using HPV16 E7 as a Model Antigen. Drug Delivery 2009; in
    press.

  • Bolhassani A., Taghikhani M., Ghasemi N., Soleimanjahi H. and Rafati S.Comparison of Two Delivery Systems Efficiency by Using Polyethylenimine (PEI) for Plasmid HPV16E7 DNA Transfection into COS-7 Cells. Modarres
    Journal of Medical Sciences, 2009; in press.

  • Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines. 2008, 7(8):1185-99. Review

  • Abtahi H, Salmanian AH, Rafati S, Nejad GB, Saffari M, Ghazavi A, Mosayebi G., The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. Pak J Biol Sci. 2008 1;11(21): 2472-7.

  • Bolhassani A., Zahedifard F., Taghikhani M and Rafati S., Enhanced immunogenecity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008, 26 (46):5822-9.

  • Adnene Salhi, Virmondes Rodrigues, Jr., Ferrucio Santoro, Helia Dessein, Audrey Romano, Lucio Roberto Castellano, Mathieu Sertorio, Sima Rafati, Christophe Chevillard, Aluisio Prata, Alexandre Alcaı¨s, Laurent Argiro, and Alain Dessein.
    Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with Leishmania braziliensis. J. Immunology, 2008 180(9):6139-48.

  • Rafati S, Zahedifard F, Kakeh Azari M , Taslimi Y, Taheri T. C-terminal Extension of cysteine proteinase type I is responsible for TH2 elicitation in experimental murine L. infantum infection. Experimental Parasitology, 2008, 118:393-401.

  • Golkar M, Rafati S, Abdel-Latif MS, Brenier-Pinchart MP, Fricker-Hidalgo H,Sima BK, Babaie J, Pelloux H, Cesbron-Delauw MF, Mercier C.The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. Diagn Microbiol Infect Dis. 2007 , 58(4):419-26

  • Golkar M, Shokrgozar MA, Rafati S, Musset K, Assmar M, Sadaie R, Cesbron-Delauw MF, Mercier C.Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine. 2007 May 22;
    25 (21):4301-11.

  • Balenga NA, Rafati S. Innate immune system: Specific or non-specific?Med Hypotheses. 2007;69(2):460-1.. No abstract available.

  • Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine. 2007 May 22;25 (21) :4159-69.

  • Rafati S, Hassani N, Taslimi Y, Movassagh H, Rochette A, Papadopoulou B. Amastin peptide-binding antibodies as biomarkers of active human visceralleishmaniasis. Clin Vaccine Immunol. 2006 Oct;13(10):1104-10.

  • Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006 Mar;123(3):423-38. Review.

  • Rafati S, Zahedifard F., Nazgouee, F. Prime-boost vaccination using Cysteine proteinases type I & II of L. infantum confers protective immunity in murine visceral leishmaniasis. Vaccine, 24(12): 2169-75, 2006.

  • Balenga NA, Zahedifard F, Weiss R, Sarbolouki MN, Thalhamer J, Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol. 2006 Jul 25;124(3):602-14.

  • Rafati S, Ghaemimanesh F, Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. Vaccine. 2006 Apr 12;24(16):3290-7.

  • Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine. 2006 Mar 15;24(12):2169-75.

  • Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P,Taghikhani M, Jamshidi S, Rad MA. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine. 2005 May 25; 23(28):3716-25.

  • Nakhaee A, Rafati S, Salmanian AH, Taghikhani M, Mohebali M., Taheri T. Immunological responses of naturally infected dogs to Type I and Type II recombinant cysteine proteinases of Leishmania infantum. Moddares J. of Medical Sciences. 2005, 8(1):55-66.

  • Golkar M., Shokrgozar M.A., Rafati S., Sadaie M.R., and Assmar M. Construction, expression and preliminary immunological evaluation of a DNA plasmid encoding the GRA2 protein of Toxoplasma gondii. Iranian Biomedical
    Journal 9 (1): 1-8, 2005.

  • Rafati S, Salmanian AH, Taheri T, Masina S, Schaff C, Taslimi Y, Fasel N. Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis.Mol Biochem Parasitol. 2004 May; 135 (1):13-20.

  • Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine. 2004 May 7;22(15-16):1930-40.

  • Zadeh-Vakili A., Taheri T., Taslimi Y., Doutdari F., Salmanian AH., and Rafati S., Bivalent DNA vaccination with genes encoding Leishmania major cysteine proteinases type I and type II protects mice against infectious challenge. Iranian Journal of Biotechnology Vol 2, No.1, 2004-10-15

  • Nakhaee A, Taheri T, Taghikhani M, Mohebali M, Salmanian AH, Fasel N, Rafati S. Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population.Vet Parasitol. 2004 Jan
    30;119(2-3):107-23.

  • Abtahi H., Salmanian AH., Rafati S., Behzadian Nejad G., Hassan ZM., High level expression of recombinant ribosomal protein (L7/L12) from Brucella abortus and its reaction with infected human sera. Iranian Biochemical Journal 2004, 8(1): 13-18.

  • Golkar M., Rafati S., Taslimi Taheri T., Doustdary F. and Assmar M. High-level expression and evaluation the M. High-level expression and evaluation the antigenicity of a recombinant Toxoplasma gondii GRA2 protein. Iranian Journal of Biotechnology, Vol. 2, No. 3, 2004.

  • Rafati S., Fasel N., Masina S., Leishmania cysteine proteinases: from gene to putative subunit vaccine. Review, Current Genomic. 2003, 4, 109-121.

  • Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjomeh M, Hejazi H, Modabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol. 2003 Nov;134(2):303-8.

  • Rafati S, Nakhaee A, Taheri T, Ghashghaii A, Salmanian AH, Jimenez M, Mohebali M, Masina S, Fasel N. Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis.Exp Parasitol. 2003 Mar-Apr;103(3-4):143-51.

  • Pascalis H, Lavergne A, Bourreau E, Prévot-Linguet G, Kariminia A, Pradinaud R, Rafati S, Launois P. Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun. 2003 May; 71(5) : 2924-6.

  • Farzaneh P, Ebtekar M, Hassan ZM, Rafati S. Murine cytokine patterns following rubella vaccination. Iran J Allergy Asthma Immunol. 2003 Jun;2(2):89-93.

  • Rafati S, Kariminia A, Seyde-Eslami S, Narimani M, Taheri T, Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine. 2002 Jun 7;20(19-20):2439-47.

  • Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.Vaccine. 2001 May 14;19(25-26):3369-75.

  • Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans.Mol Biochem Parasitol. 2001 Mar;113(1):35-43.

  • Rafati S, Baba AA, Bakhshayesh M, Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin Exp Immunol. 2000 Apr;120(1):134-8.

  • Solioz N, Blum-Tirouvanziam U, Jacquet R, Rafati S, Corradin G, Mauël J, Fasel N. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 1999 Dec 10;18(9-10):850-9.

  • Rafati S, Couty-Jouve S, Alimohammadian MH, Louis JA. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. Clin Exp Immunol. 1997 Nov;110(2):203-11.

  • Rafati, S., Couty-Jouv S., Dowlati Y., Alimohammadian, MH., (1997) Evaluation of cellular immune responses of recovered human cutaneous leishmaniasis to amastigote soluble L. major antigen. Medical Journal of the Islamic Republic of Iran. Vol. 11, No. 1, 33-38
     

  • Golkar M, Rafati S., Assmar M, Cesbron-Delauw MF, Mercier C.
    Expression level and solubility of the toxoplasma recombinant dense granule protein GRA2 is enhanced by fusion with thioredoxin, Submitted to Protein Expression and Purification  2005

  • Aghaei, N., Zahedifard F. Sarbouloki and Rafati S.
    Characterization of the protective efficiency of Den123 as a novel nano-sized adjuvant for DNA vaccination against birch pollen allergy, Submitted to J. of Biotechnology 2005

  • Rafati S, Ghaemi-Manesh F, Zahedi-Fard F.
    Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I, in BALB/c mice. Submitted to Vaccine 2005

  • Rafati S, Zahedifard F., Nazgouee, F.
    Prime-boost vaccination using Cysteine proteinases type I & II of L. infantum confers protective immunity in murine visceral leishmaniasis. Vaccine, in Press 2005.

  • Golkar M., Shokrgozar M.A., Rafati S., Sadaie M.R., and Assmar M.
    Contruction, expression and preliminary immunological evaluation of a DNA plasmid encoding the GRA2 protein of Toxoplasma gondii. Iranian Biomedical Journal 9 (1): 1-8, 2005.

  • Golkar M., Rafati S., Taslimi Taheri T., Doustdary F.  and Assmar M.
    High-level expression and evaluation the M. High-level expression and evaluation the antigenicity of a recombinant Toxoplasma gondii GRA2 protein. Iranian Journal of Biotechnology, Vol. 2, No. 3, 2004.

  • Rafati S., Nakhaee AR, Taheri T, Taslimi Y. , Darabi H, Eravani E.  Sanos S, Kaye P, Taghikhani M, Jamshidi S,  Rad MA
    Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum , Vaccine, 2005, 23:3716-3726

  • Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S., Momeni AZ, Moddaber F.
    Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clinical Experimental Immunology 2003,134: 303-308

  • Abtahi H., Salmanian AH., Rafati S., Behzadian Nejad G., Hassan ZM.
    High level expression of recombinant ribosomal protein (L7/L12) from Brucella abortus and its reaction with infected human sera. Iranian Biochemical Journal 2004, 8(1): 13-18.

  • Farzaneh P, Ebtekar M, Hassan ZM, Rafati S.
    Murine cytokine patterns following Rubella vaccination. Iranian Journal of Allergy, Asthema and Immunology. 2003, Vol 2, No. 2, 89-93

  • Zadeh-Vakili A., Taheri T., Taslimi Y., Doutdari F., Salmanian AH., and Rafati S.
    Bivalent DNA vaccination with genes encoding Leishmania major cysteine proteinases type I and type II protects mice against infectious challenge. Iranian Journal of Biotechnology Vol 2, No.1, 2004-10-15

  • Rafati S., Salmanian AH, Taheri T., Masina S., Schaff C. Taslimi Y., Fasel N.
    Type I signal peptidase from Leishmania major is a target of the immune response in human cutaneous and visceral leishmaniasis, Molecular and Biochemical Parasitology, 2004, 135:13-20.

  • Nakhaee A., Taheri T., Taghikhani M., Mohebali M., Salmanian AH., Fasel N., and Rafati S.
    Humoral and cellular immune responses against Type I cysteine proteinases of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population. Veterinary parasitology, 2004, 119:107-123.

  • Zadeh-Vakili A., Taheri T., Taslimi Y., Doutdari F., Salmanian AH., and Rafati S.
    Immunization with a hybrid protein vaccine consisting of Leishmania major cysteine proteinases type I (cpb) and type II (CPA) partially protects against leishmaniasis. Vaccine 2004, 22:1930-1940.

  • Rafati, S., Nakhaee A., Tahere T., Ghashghaii, A., Salmanian AH., Jimenez M., Mohebali M., Masina S.,  Fasel N.
    Expression of cysteine proteinases Type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Experimental Parasitology 2003, 103:143-151.

  • Pascalis H., Lavergne A., Bourreau E., Kariminia A., Pradinaud R, Rafati, S., Launois P.
    Th1 Cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis. Infection and Immunity 2003, 2924-2926.

  • Rafati S., Fasel N., Masina S.
    Leishmania cysteine proteinases: from gene to putative subunit vaccine. Review, Current Genomic. 2003, 4, 109-121.

  • Rafati S., Kariminia A, Syde-Eslami S, Narimani M, Taheri T, Lebbatard M. 
    Recombinant Cysteine Proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8+ T lymphocyte activation. Vaccine 2002,20:2439-2447

  • Rafati S., Salmanian AH., Taheri T., Vafa M., Fasel N.
    A protective cocktail DNA vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine, 2001 19(25-26):3369-75.

  • Rafati, S.  Salmanian H., Katayon Hashemi, Schaff C., Belli S., Fasel N.
    Identification of Leishmania major cysteine proteinases as targets of the immune response in human. Molecular and biochemical parasitology 2001, 113(1): 35-43.

  • Solioz, N., Blum-Tirouvanziam, U., Raymond, J., Rafati, S., Corradin, G., Mauel, J., Fasel, N.
    The protective capacities of a nuclear antigen against experimental murine cutaneous leishmaniasis, Vaccine, 1999, 18: 850-859.

  • Rafati, S., Abraham Baba, A., Bakhshayesh, M., Vafa M.
    Vaccination of BALB/c mice with 24 kDa antigens of amastigote form of Leishmania major , Clinical and Experimental Immunology,  2000 120: 134-138.

  • Rafati, S., Couty-Jouve, S., Alimohammadian, MH., Louis J.A., (1997)
    Biochemical analysis and immunogenecity of L. major amastigote fractions in cutaneous leishmaniasis. Clinical Exp. Immunol  110: 203-211

  • Rafati, S., Couty-Jouv S., Dowlati Y., Alimohammadian, MH., (1997)
    Evaluation of cellular immune responses of recovered human cutaneous leishmaniasis to amastigote soluble L. major antigen. Medical Journal of the Islamic Republic of Iran.Vol. 11, No. 1, 33-38

 

 
Copyright © 2005
Pasteur Institute of Iran.
Photo Gallery    |    Projects    |    International Support    |    Patent    |    Publication    |    Contacts